When an intervention fails to help

Category: Safety · Editorial Review: Updated 20 October 2026 · 3 minute read

Set the evaluation before treatment

Agree on the outcome to assess, the baseline measurement, and the time point for review. The measure should relate to the goal that mattered in the consultation. Without this plan, improvement may be judged by selective impressions while lack of response is repeatedly explained away.

Review competing explanations

Symptoms may change because of rehabilitation, medicines, rest, natural fluctuation, or progression of disease. A follow-up clinician should consider these factors rather than assuming that every change results from the cell intervention. Ask whether a new assessment or a return to established care is the most appropriate next step.

Repetition needs justification

Before paying for more treatment, ask what evidence supports another dose in someone who did not respond, what additional risks arise, and whether the plan has a stopping rule. Keep your records and obtain an independent opinion if the explanation remains unclear. A prepaid package is not a clinical reason to continue.

Putting the discussion into practice

If the clinic says results will appear later each time a review passes, ask for a written reassessment of the original timeline. It may be reasonable to continue observation, but that is different from purchasing another intervention. Keep track of functional measures and other treatment changes so a reviewing clinician can evaluate what happened. A clear stopping plan protects both medical and financial decision-making.

Questions to take to the consultation

Ask: What was the original success measure? Has it changed, and why? What evidence supports repeating treatment after no response? What alternatives should now be considered? A useful review can acknowledge disappointment without converting it into pressure to buy another course. Request copies of follow-up measurements and an explanation of the next decision point, including the option of stopping the intervention and pursuing other established care. Discuss whether further testing would actually change management. Repeating expensive panels without a clear decision purpose can add burden while leaving the central question unanswered. Follow-up should connect information to a practical plan for symptoms, function, and ongoing care.

Continue exploring

• Cell treatment safety: separate three kinds of risk
• Why your own cells do not mean zero risk
• Infection and cell-based procedures
• Prepare your consultation checklist

Sources & further reading

• ISSCR patient guide

Read alongside your treating specialist’s advice. Clinical eligibility, exact products and treatment plans require individual assessment.